SEC 13F Intelligence

Managers / Q4 2021 · view latest →

Rock Springs Capital Management LP

CIK 0001595725 · 650 SOUTH EXETER STREET, SUITE 1070, BALTIMORE, MD, 21202 · 4102200129

Reported Value
$4.3B
Q4 2021
Positions
136
Filings on Record
30
2019–present window
Filed
Feb 14, 2022
original filing

Summary

Rock Springs Capital Management LP reported $4.3B in U.S.-listed holdings across 136 positions for Q4 2021.

Its largest position, Agilon Health, represents 4.7% of the portfolio.

Compared with Q3 2021, the fund opened 4 new positions and exited 21.

Portfolio Metrics

Turnover
+8.1%
vs prior filed quarter
Top-10 Concentration
+30.2%
share of reported value
Largest Position
+4.7%
Agilon Health
New / Exited
4 / 21
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $2.1BQ4 ’18Q1 ’19: $2.6BQ2 ’19: $2.8BQ3 ’19: $2.5BQ4 ’19: $3.2BQ4 ’19Q1 ’20: $2.4BQ2 ’20: $3.6BQ3 ’20: $3.9BQ4 ’20: $4.7BQ4 ’20Q1 ’21: $4.6BQ2 ’21: $5.1BQ3 ’21: $4.8BQ4 ’21: $4.3BQ4 ’21Q1 ’22: $4.0BQ2 ’22: $3.4BQ3 ’22: $3.9BQ4 ’22: $4.2BQ4 ’22Q1 ’23: $4.2BQ2 ’23: $4.2BQ3 ’23: $3.7BQ4 ’23: $4.1BQ4 ’23Q1 ’24: $3.9BQ2 ’24: $3.3BQ3 ’24: $3.1BQ4 ’24: $2.6BQ4 ’24Q1 ’25: $1.7BQ2 ’25: $1.6BQ3 ’25: $1.7BQ4 ’25: $2.0BQ4 ’25Q1 ’26: $1.7Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 74.7%Other: 16.7%ADR: 7.2%US DOMESTIC: 1.4%Equity WRT: 0.0%
  • Common Stock · 74.7% · $3.2B
  • Other · 16.7% · $725M
  • ADR · 7.2% · $310M
  • US DOMESTIC · 1.4% · $60M
  • Equity WRT · 0.0% · $253,000

Quarter-over-Quarter Changes full breakdown →

vs Q3 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
XILIO THERAPEUTICS INCNEW+1.19M1.19M+$19M$19M
AURAAURA BIOSCIENCES INCNEW+1.01M1.01M+$17M$17M
CMPXCOMPASS THERAPEUTICS INCNEW+5.33M5.33M+$17M$17M
THESEUS PHARMACEUTICALS INCNEW+437.3K437.3K+$6M$6M
ISRGINTUITIVE SURGICAL INCADDED+240.0K360.0K+$10M$129M
OVASUSDTEMPEST THERAPEUTICS INCADDED+513.5K823.7K−$139,000$4M
TFXTELEFLEX INCORPORATEDSOLD OUT−130.0K0−$49M$0
ALLKGUSDALLAKOS INCSOLD OUT−305.7K0−$32M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2021

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1AGILON HEALTH INCCOM4.68%$202M7.50M
2HUMHUMANA INChistory →COM3.74%$162M349.0K
3AFWALIGN TECHNOLOGY INChistory →COM3.04%$131M200.0K
4ISRGINTUITIVE SURGICAL INChistory →COM NEW2.99%$129M360.0K
5PODDINSULET CORPhistory →COM2.85%$123M463.8K
6UNHUNITEDHEALTH GROUP INChistory →COM2.78%$121M240.0K
7IDXXIDEXX LABS INChistory →COM2.74%$119M180.0K
8HCAHCA HEALTHCARE INChistory →COM2.67%$116M450.0K
9ARGXARGENX SEhistory →SPONSORED ADR2.55%$110M315.0K
10NBIXNEUROCRINE BIOSCIENCES INChistory →COM2.17%$94M1.10M
112655787DBLUEPRINT MEDICINES CORPhistory →COM2.13%$92M859.8K
12AGIOAGIOS PHARMACEUTICALS INChistory →COM2.01%$87M2.65M
13IMCRIMMUNOCORE HLDGS PLChistory →ADS1.96%$85M2.47M
14HORIZON THERAPEUTICS PUB LSHS1.86%$80M746.0K
15EWEDWARDS LIFESCIENCES CORPhistory →COM1.74%$75M582.0K
16RAREULTRAGENYX PHARMACEUTICAL INhistory →COM1.72%$74M883.9K
17ZLABZAI LAB LTDhistory →ADR1.71%$74M1.18M
18BAXBAXTER INTL INChistory →COM1.46%$63M733.8K
19NVV1NOVAVAX INChistory →COM NEW1.40%$61M425.0K
20MRTXEURMIRATI THERAPEUTICS INChistory →COM1.39%$60M410.4K
21PCRXPACIRA BIOSCIENCES INChistory →COM1.39%$60M1.00M
22NVROEURNEVRO CORPhistory →COM1.34%$58M714.0K
23EVHEVOLENT HEALTH INChistory →CL A1.30%$56M2.04M
24ALNYALNYLAM PHARMACEUTICALS INChistory →COM1.30%$56M332.5K
25ACRSACLARIS THERAPEUTICS INChistory →COM1.30%$56M3.86M
26KARUNA THERAPEUTICS INCCOM1.29%$56M426.8K
27FRPTFRESHPET INChistory →COM1.28%$55M580.0K
28ASCENDIS PHARMA A/SSPONSORED ADR1.24%$54M400.0K
29CEREVEL THERAPEUTICS HLDNG ICOM1.23%$53M1.65M
30IRTCIRHYTHM TECHNOLOGIES INChistory →COM1.18%$51M433.0K
31KYMRKYMERA THERAPEUTICS INChistory →COM1.09%$47M742.1K
32ACHCACADIA HEALTHCARE COMPANY INhistory →COM1.05%$45M748.5K
33EXKEXACT SCIENCES CORPhistory →COM1.02%$44M570.0K
34INVITAE CORPCOM0.99%$43M2.80M
35PENPENUMBRA INChistory →COM0.99%$43M148.5K
36SWAVUSDSHOCKWAVE MED INChistory →COM0.92%$40M222.5K
37SGENUSDSEAGEN INChistory →COM0.91%$40M256.0K
38SRPTSAREPTA THERAPEUTICS INChistory →COM0.88%$38M424.0K
39ARVNARVINAS INChistory →COM0.87%$38M457.2K
40CYTOKINETICS INCNOTE 4.000%11/10.82%$36M8.00M
41WRBYWARBY PARKER INChistory →CL A COM0.78%$34M724.0K
42HCATHEALTH CATALYST INChistory →COM0.78%$34M850.2K
43VERVE THERAPEUTICS INCCOM0.77%$33M902.9K
44CVETUSDCOVETRUS INChistory →COM0.77%$33M1.66M
45EHCENCOMPASS HEALTH CORPhistory →COM0.76%$33M502.5K
46PHRPHREESIA INChistory →COM0.74%$32M770.0K
47PROTHENA CORP PLCSHS0.74%$32M647.7K
48ACCDUSDACCOLADE INChistory →COM0.73%$32M1.20M
49DC4DEXCOM INChistory →COM0.70%$30M56.8K
50TVTXTRAVERE THERAPEUTICS INChistory →COM0.68%$30M951.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$1.7B100May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$2.0B99Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$1.7B93Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$1.6B93Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$1.7B96May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$2.6B107Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$3.1B109Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$3.3B112Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$3.9B114May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$4.1B104Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$3.7B120Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$4.2B123Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$4.2B121May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$4.2B120Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$3.9B128Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$3.4B131Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$4.0B135May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$4.3B136Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$4.8B153Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$5.1B156Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$4.6B151May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$4.7B155Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$3.9B148Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$3.6B143Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$2.4B131May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$3.2B130Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$2.5B138Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$2.8B135Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$2.6B131May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$2.1B133Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.